HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Neurogene (NASDAQ:NGNE) and maintained a $45 price target on the company's stock.
January 17, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Neurogene and maintained a $45 price target.
The reiteration of a Buy rating and the maintenance of a $45 price target by a reputable analyst could lead to increased investor confidence in Neurogene, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100